- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Romosozumab Effective in RA and Primary Osteoporosis: Study
Romosozumab increased bone mineral density (BMD) and decreased bone turnover in patients with co-occurring rheumatoid arthritis and osteoporosis (RA-OP) and patients with primary osteoporosis (P-OP), according to study results presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2021, held from October 1 to 4, 2021, in San Diego, California, and real-time virtually.
Patients with RA-OP and P-OP were included in the study if they had a BMD T score of -2.5 or less at the lumbar spine or hip and either 1 or more moderate or severe vertebral fractures or 2 or more mild vertebral fractures. All patients received 210 mg romosozumab once per month for more than 6 months. Researchers measured BMD and T-scores of the lumbar spine and hip and bone turnover markers including procollagen I N-terminal propeptide (PINP) and tartrate-resistant acid phosphatase 5b (TRACP-5b) during the 12-month study period.
Among 48 patients (14 with RA-OP and 34 with P-OP), 47 were women. Mean age of patients was 73.4±9.3 years, with a body mass index of 20.4±3.8 and high fracture risk assessment (FRAX) scores of 36.4±16.8. Duration of RA in patients with RA-OP was 19.9±16.4 years. Baseline RA indices for patients with RA-OP included C-reactive protein (CRP) 0.58±0.59, disease activity score (DAS28-CRP) 3.39±0.93, and health assessment questionnaire disability index (HAQ) 1.63±0.94. Baseline bone measurements for all patients were PINP 83.2±77.9, TRACP-5b 525±291, lumbar spine BMD 0.79±0.15 g/cm2, lumbar spine BMD T-score -2.80±1.03, hip BMD 0.57 ± 0.08 g/cm2, and hip BMD T-score -3.04±0.62. Over a period of 12 months, the researchers observed a decrease in TRAC-5b biomarker levels and increase in PINP and BMD (lumbar and hip) from baseline.
The results of the study are as follows:
The rate of decrease in TRAC-5b from baseline to 1, 3, 6 and 12 months was -19.4%±25.3%, -10.0%±31.6%, -8.9%±51.8%, and -11.6%±60.2%, respectively.
- The rate of increase in PINP from baseline to 1, 3, 6 and 12 months was 105.2%±90.8%, 87.3%±100.7%, 66.5%±143.1%, and 30.8%±146.6%, respectively.
- The rate of increase in lumbar spine BMD from baseline to 6 and 12 months was 10.3%±7.3% and 14.6%±9.9%, respectively.
- For hip BMD, the rate of increase from baseline to 6 and 12 months was 3.8%±5.6% and 6.6%±7.8% respectively.
Thus, the researchers concluded that clinical efficacy of romosozumab for RA-OP and P-OP was extremely effective for 12 months and has the high potential to be an important option in the treatment of osteoporosis."
Reference
Kanayama Y, Tsuji T, Futamura N, Ota K, Watanabe T, Teresawa K, Maeda K. Clinical efficacy of romosozumab in patients with rheumatoid arthritis and primary osteoporosis for 12 months. Presented at: ASBMR Annual Meeting 2021; October 1-4, 2021; San Diego, CA. Abstract VPP-647.
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751